This study is testing a new medicine called daraxonrasib to see if it helps people with a type of cancer called Pancreatic Ductal Adenocarcinoma (PDAC) live longer without the cancer coming back after surgery. The study compares daraxonrasib to the usual care, which is just watching and waiting. PDAC is a cancer that starts in the tubes of the pancreas. The study is in Phase 3, which means it's in the later stages of testing. Patients must be at least 18 years old, have had successful surgery to remove the cancer, and finished chemotherapy treatment recently. The study checks if patients can take pills and if their organs are working well. People who have taken certain cancer medicines before or can't follow study rules can't join.

• Duration: Participation involves ongoing check-ups and evaluations.
• Visits: Regular visits to the study site are required.
• Compensation: Details on compensation are not provided.